Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's EBIT?
- Allogene Therapeutics (ALLO) reported EBIT of -$46.09M in Q1 2026.
- How has Allogene Therapeutics's EBIT changed year-over-year?
- Allogene Therapeutics's EBIT increased by 29.3% year-over-year, from -$65.19M to -$46.09M.
- What is the long-term trend for Allogene Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Allogene Therapeutics's EBIT has grown at a 3.6% compound annual growth rate (CAGR), from -$181.9M to -$209.32M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Allogene Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude